Pharmacological interventions according to actionable genomic
alterations
At least one genetic aberration was detected in 11 patients (84.6%).
Actionable mutations were discovered in 10 patients (76.9%), and the
median number of actionable alterations in our cohort was 2.0 (range,
0–6). Seven patients (53.8%) had clinical trial candidates. However,
no patients were able to receive biomarker-matched therapy according to
their genomic alterations.